$bluebird bio (BLUE.US)$ bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition Positive 94.7% of evaluable patients achieved complete resolution of severe VOEs 86.8% of evaluable patients achieved complete resolution of VOEs 100% success rate in pediatric patients (10/10) for VOE resolution No stroke recurrence in patients with prior history through 9 y...
$bluebird bio (BLUE.US)$Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or Near-Normal Adult Hb Levels At ASH Meeting bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
$bluebird bio (BLUE.US)$ bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition Sunday, 8th December at 12:30 pm Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
$MSP Recovery (LIFW.US)$Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB $Roth CH Acquisition V Co (ROCL.US)$Ticker change tomorr...
36
24
4
Report
105642463xu
:
It's a good idea not to hold it overnight, otherwise you‘ll be doomed if you fall asleep like me.
$bluebird bio (BLUE.US)$ Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels Saturday, 7th December at 12:00 pm Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up bluebird...
News Highlights On Friday evening,$Super Micro Computer (SMCI.US)$revealed that Nasdaq had approved their appeal for additional time to submit crucial documents. Following this news, Super Micro's shares saw a significant increase after trading hours, furthering its impressive recovery since mid-November. The most traded calls are contracts of $45 strike price that expire on Dec. 6. The total v...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Positive
94.7% of evaluable patients achieved complete resolution of severe VOEs
86.8% of evaluable patients achieved complete resolution of VOEs
100% success rate in pediatric patients (10/10) for VOE resolution
No stroke recurrence in patients with prior history through 9 y...
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Sunday, 8th December at 12:30 pm
Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
$Roth CH Acquisition V Co (ROCL.US)$ Ticker change tomorr...
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Saturday, 7th December at 12:00 pm
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up
bluebird...
Increased Positions
$D.R. Horton (DHI.US)$ , $Johnson & Johnson (JNJ.US)$ , $Coca-Cola (KO.US)$ , $iShares MSCI China ETF (MCHI.US)$
New Positions
$Vanguard Financials ETF (VFH.US)$ , $Utilities Select Sector SPDR Fund (XLU.US)$ , $UnitedHealth (UNH.US)$
Decreased / Sold out Positions
None
loading...
On Friday evening, $Super Micro Computer (SMCI.US)$ revealed that Nasdaq had approved their appeal for additional time to submit crucial documents. Following this news, Super Micro's shares saw a significant increase after trading hours, furthering its impressive recovery since mid-November.
The most traded calls are contracts of $45 strike price that expire on Dec. 6. The total v...
watch for 26.42 breakout
No comment yet